COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review of the potential mechanisms and proposed management
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
SAGE Publications Ltd
Abstract
With over 600 million coronavirus (COVID-19) vaccine doses administered globally, adverse events are constantly monitored. Recently however, reports of thrombosis and thrombocytopenia following vaccination with the ChAdOx1 nCoV-19 vaccine have emerged. This paper aims to review the available literature and guidelines pertaining to vaccine-induced immune thrombotic thrombocytopenia (VITT) and the proposed guidelines, while offering a potential approach that unifies the available evidence. While the risk of VITT remains extremely low and the benefits outweigh the risks, experimental studies are needed to clarify the pathophysiology behind VITT and possibly decrease the risk of thrombosis and other adverse events occurring. However, treatment should not be delayed in suspected cases, and IV immunoglobulin and non-heparin anticoagulation should be initiated. © The Author(s) 2021.
Description
Keywords
Chadox1 ncov-19, Covid-19, Thrombocytopenia, Thrombosis, Thrombosis with thrombocytopenia syndrome, Tts, Vaccine-induced immune thrombotic thrombocytopenia, Vaccine-induced prothrombotic immune thrombocytopenia, Vipit, Vitt, Anticoagulants, Antithrombins, Autoantibodies, Biomarkers, Covid-19 vaccines, Factor xa inhibitors, Fibrin fibrinogen degradation products, Fondaparinux, Heparin, Humans, Immunoglobulins, intravenous, Practice guidelines as topic, Purpura, thrombocytopenic, idiopathic, Sars-cov-2, Anticoagulant agent, Antithrombin, Autoantibody, Biological marker, Blood clotting factor 10a inhibitor, Chadox1 covid-19 vaccine, Fibrin degradation product, Fibrin fragment d, Immunoglobulin, Adverse event, Blood, Epidemiology, Human, Idiopathic thrombocytopenic purpura, Immunology, Metabolism, Pathogenicity, Pathology, Practice guideline, Prevention and control